Context Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
CNTX$0.20+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Acquired in-process research and development | $— | $500,000 |
| Research and development | 17,782,731 | 7,091,163 |
| General and administrative | 7,289,885 | 7,790,040 |
| Loss from operations | (25,072,616) | (15,381,203) |
| Interest income | 1,163,975 | 547,268 |
| Other expense | (55,570) | (2,004) |
| Net loss | $(23,964,211) | $(14,835,939) |
| Net loss per common share, basic and diluted | $(1.50) | $(0.93) |
| Weighted average shares outstanding, basic and diluted | 15,966,053 | 15,966,053 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.